Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
DOI:
https://doi.org/10.2340/00015555-3815Keywords:
psoriasis, biologics, dose reduction, daily practiceAbstract
Dose reduction of biologics for psoriasis could contribute to lower drug exposure. This study evaluated a one-step, tightly controlled, biologic dose reduction strategy in a prospective daily practice cohort. In patients with psoriasis with low disease activity using adalimumab, etanercept or ustekinumab for at least 6 months, the dosing interval was prolonged with 33%. Patients could return to their normal dosing interval in case of disease flare. Of 108 eligible patients, 80 started dose reduction and were analysed. In total, 36/80 patients (45.0%) discontinued dose reduction after 19 months (95% confidence interval 14.9–23.1 months). Of 67 patients with 1-year follow-up, 45 (67.2%) still used the lower dose after 1 year. No serious adverse events related to dose reduction occurred. Cumulative dose and costs decreased by 22.7% during 1 year. In conclusion, a one-step tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab has considerable potential to safely decrease biologic dosages in patients with psoriasis in daily practice.
Downloads
References
Atalay S, van den Reek J, den Broeder AA, van Vugt LJ, Otero ME, Njoo MD, et al. Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial. JAMA Dermatol 2020; 156: 393-400.
DOI: https://doi.org/10.1001/jamadermatol.2019.4897
Taniguchi T, Noda S, Takahashi N, Yoshimura H, Mizuno K, Adachi M. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment. J Eur Acad Dermatol Venereol 2013; 27: 1444-1447.
DOI: https://doi.org/10.1111/j.1468-3083.2012.04610.x
Baniandres O, Rodriguez-Soria VJ, Romero-Jimenez RM, Suarez R. Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting. Actas Dermosifiliogr 2015; 106: 569-577.
DOI: https://doi.org/10.1016/j.adengl.2015.06.004
Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, et al. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol 2017; 177: 1552-1561.
DOI: https://doi.org/10.1111/bjd.15722
van Bezooijen JS, van Doorn MBA, Schreurs MWJ, Koch BCP, Te Velthuis H, Prens EP, et al. Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study. Ther Drug Monit 2017; 39: 379-386.
DOI: https://doi.org/10.1097/FTD.0000000000000420
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440.
DOI: https://doi.org/10.1001/archderm.1997.03890470111018
De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138: 1221-1227; discussion 1227.
DOI: https://doi.org/10.1001/archderm.138.9.1221
Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713.
DOI: https://doi.org/10.1111/1523-1747.ep12365600
Castor Electronic Data Capture 2018 [cited 2020 July 22]. Available from: www.castoredc.com.
van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lumig PP, Driessen RJ, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 2014; 171: 1189-1196.
DOI: https://doi.org/10.1111/bjd.13087
Website medication costs: National Health Care Institute the Netherlands; 2020 [cited 2020 July 22]. Available from: www.medicijnkosten.nl.
van Lumig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013; 68: 57-63.
DOI: https://doi.org/10.1016/j.jaad.2012.05.040
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
DOI: https://doi.org/10.1111/j.1365-2133.2008.08832.x
Prinsen CA, Lindeboom R, de Korte J. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol 2011; 131: 1945-1947.
DOI: https://doi.org/10.1038/jid.2011.138
Puig L, Carrascosa JM, Carretero G, de la Cueva P, Lafuente-Urrez RF, Belinchón I, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013; 104: 694-709.
DOI: https://doi.org/10.1016/j.ad.2013.04.003
Hamadah IR, Al Raddadi AA, Bahamdan KA, Fatani MI, Alnahdi A, Al Rakban AM, et al. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat 2015; 26: 223-229.
DOI: https://doi.org/10.3109/09546634.2014.946882
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol 2017; 76: 290-298.
DOI: https://doi.org/10.1016/j.jaad.2016.10.017
Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016; 30: 1-18.
DOI: https://doi.org/10.1111/jdv.13542
Grine L, de la Brassinne M, Ghislain PD, Hillary T, Lambert J, Segaert S, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol 2020; 34: 676-684.
DOI: https://doi.org/10.1111/jdv.16104
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.
DOI: https://doi.org/10.1111/bjd.18333
Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol 2021; 35: 417-421.
DOI: https://doi.org/10.1111/jdv.16966
Otero ME, van Geel MJ, Hendriks JC, van de Kerkhof PC, Seyger MM, de Jong EM. A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: presentation and implications of the low PASI score. J Dermatolog Treat 2015; 26: 314-317.
DOI: https://doi.org/10.3109/09546634.2014.972316
Michielsens CAJ, van Muijen ME, Verhoef LM, van den Reek J, de Jong E. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs 2021; 81: 349-366.
DOI: https://doi.org/10.1007/s40265-020-01448-z
Atalay S, van den Reek J, Groenewoud J, van de Kerkhof P, Kievit W, de Jong E. Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice. J Dermatolog Treat 2021 Jan 7 [Online ahead of print].
DOI: https://doi.org/10.1080/09546634.2020.1869147
Atalay S, van den Reek J, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol 2020; 100: adv00340.
Published
How to Cite
License
Copyright (c) 2021 Selma Atalay, Lara S. van der Schoot, Laura Vandermaesen, Lieke J. van Vugt, Mascha Eilander, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
